Balstilimab: Anti-PD-1 Antibody

Enrolling in second-line cervical cancer

NCT03104699

Phase 2 expansion to evaluate efficacy in subjects with recurrent, unresectable, or metastatic (advanced) cervical cancer that has progressed after a platinum-based treatment regimen

Visit clinicaltrials.gov

Enrolling in second-line cervical cancer

NCT03894215

Randomized, blinded, non-comparative, two-arm Phase 2 clinical trial to assess the efficacy and safety of AGEN2034 administered with placebo (Treatment Arm 1 – monotherapy) or with AGEN1884 (Treatment Arm 2 – combination therapy) for treatment of patients with advanced cervical cancer who relapsed or progressed after receiving first-line platinum-based chemotherapy

Visit clinicaltrials.gov

Zalifrelimab: Anti-CTLA-4 Antibody

Enrolling in second-line cervical cancer

NCT03495882

Phase 1/2, open-label study of AGEN1884 in combination with AGEN2034 in subjects with locally advanced, recurrent and/or metastatic solid tumors including cervical cancer

Visit clinicaltrials.gov

Enrolling in cancers that have progressed after PD-1/PD-L1 inhibitor as the most recent therapy

NCT02694822

Phase 1/2, multicenter study to evaluate the safety, PK, and PD of an anti-CTLA-4 human monoclonal antibody (AGEN1884) in subjects with advanced or refractory cancer and in subjects who have progressed during treatment with a PD-1/PD-L1 inhibitor as their most recent therapy

Visit clinicaltrials.gov

AGEN1181: Next-generation Anti-CTLA-4 Antibody

Enrolling in solid tumors

NCT03860272

Phase 1, multicenter study to evaluate the safety, tolerability, PK, and PD profiles of a novel Fc-engineered IgG1 anti-CTLA-4 human monoclonal antibody (AGEN1181) monotherapy and in combination with a human monoclonal IgG4 antibody (AGEN2034)

Visit clinicaltrials.gov

AGEN2373: CD137 agonist

Enrolling in solid tumors

NCT04121676

Phase I open-label, 3+3 dose escalation design Phase I trial to assess the safety, tolerability and dose-limiting toxicity (DLT) of AGEN2373 as monotherapy in subjects with solid tumors

Visit clinicaltrials.gov

AGEN1223: Regulatory T cell depletion (bispecific)

Enrolling in solid tumors

NCT04156100

Phase 1 study to evaluate the safety, tolerability, PK, and pharmacodynamic profiles of AGEN1223 and to assess the maximum tolerated dose (MTD) in subjects with advanced solid tumors

Visit clinicaltrials.gov